Abstract:

We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.

日本語要旨:

次世代シークエンサーを用いた肺がんのRNA-Seqにより、新規のドライバー変異としてKIF5B-RET融合遺伝子を同定。国際共同研究により海外でも症例を確認。日本人肺腺がんの2％に存在すると考えられ、RET阻害剤による医師主導臨床試験へ発展。